AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

Shots:

• The P-II (NCT02130882) study involves assessing of Fasenra (benralizumab,30mg, q4w) vs PBO in 20 patients with HES who had at least 1,000 eosinophils/µL of blood
• The P-II (NCT02130882) clinical study results: @12wks. reduction in absolute blood eosinophil counts >50% (90% vs 30%); @48wks.maintained reduction in eosinophil counts (74%); patients taper off other HES therapies (64%), Published at New England Journal of Medicine
• Fasenra (benralizumab, SC, q4w) is a mAb targeted IL-5 receptor presented at the surface of eosinophils and has also received approval for eosinophilic asthma in US, EU, Japan with FDA’s ODD for HES. Kyowa Hakko in-licensed Fasenra from AZ

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter